These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 27916939)

  • 21. Pathogenesis of Autoimmune Hepatitis-Cellular and Molecular Mechanisms.
    Sirbe C; Simu G; Szabo I; Grama A; Pop TL
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948375
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Animal models for autoimmune hepatitis.
    Christen U; Holdener M; Hintermann E
    Autoimmun Rev; 2007 Apr; 6(5):306-11. PubMed ID: 17412303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Different sites of xenoantigen delivery lead to a virally induced late-onset hepatitis in mice through molecular mimicry.
    Piché C; Béland K; Lapierre P; Massie B; Alvarez F
    Liver Int; 2011 Oct; 31(9):1306-14. PubMed ID: 22093453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An Update on Animal Models of Autoimmune Hepatitis: Are we There Yet?
    Christen U; Hintermann E
    Curr Pharm Des; 2015; 21(18):2391-400. PubMed ID: 25777755
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Usefulness of liver infiltrating CD86-positive mononuclear cells for diagnosis of autoimmune hepatitis.
    Kurokohchi K; Masaki T; Himoto T; Deguchi A; Nakai S; Morishita A; Yoneyama H; Kimura Y; Watanabe S; Kuriyama S
    World J Gastroenterol; 2006 Apr; 12(16):2523-9. PubMed ID: 16688797
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Autoimmune hepatitis].
    Sulz MC; Gerlach TJ
    Ther Umsch; 2011 Apr; 68(4):189-94. PubMed ID: 21452139
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Autoantibodies against CYP2D6 and other drug-metabolizing enzymes in autoimmune hepatitis type 2.
    Mizutani T; Shinoda M; Tanaka Y; Kuno T; Hattori A; Usui T; Kuno N; Osaka T
    Drug Metab Rev; 2005; 37(1):235-52. PubMed ID: 15747502
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Novel therapeutic targets in autoimmune hepatitis.
    Taubert R; Hupa-Breier KL; Jaeckel E; Manns MP
    J Autoimmun; 2018 Dec; 95():34-46. PubMed ID: 30401504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Epigenetic considerations and the clinical reevaluation of the overlap syndrome between primary biliary cirrhosis and autoimmune hepatitis.
    Wang Q; Selmi C; Zhou X; Qiu D; Li Z; Miao Q; Chen X; Wang J; Krawitt EL; Gershwin ME; Han Y; Ma X
    J Autoimmun; 2013 Mar; 41():140-5. PubMed ID: 23187010
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of genetic predisposition and autoimmune hepatitis inducing antigens in disease development.
    Hardtke-Wolenski M; Dywicki J; Fischer K; Hapke M; Sievers M; Schlue J; Anderson MS; Taubert R; Noyan F; Manns MP; Jaeckel E
    J Autoimmun; 2017 Mar; 78():39-45. PubMed ID: 27974250
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adaptive immunity in autoimmune hepatitis.
    Longhi MS; Ma Y; Mieli-Vergani G; Vergani D
    Dig Dis; 2010; 28(1):63-9. PubMed ID: 20460892
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Presence of antimitochondrial autoantibodies in patients with autoimmune hepatitis.
    Nezu S; Tanaka A; Yasui H; Imamura M; Nakajima H; Ishida H; Takahashi S
    J Gastroenterol Hepatol; 2006 Sep; 21(9):1448-54. PubMed ID: 16911691
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The therapeutic effects of Yongdamsagan-tang on autoimmune hepatitis models.
    Park J; Kim H; Lee IS; Kim KH; Kim Y; Na YC; Lee JH; Jang HJ
    Biomed Pharmacother; 2017 Oct; 94():244-255. PubMed ID: 28763748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autoimmune hepatitis: Contrasts and comparisons in children and adults - a comprehensive review.
    Floreani A; Liberal R; Vergani D; Mieli-Vergani G
    J Autoimmun; 2013 Oct; 46():7-16. PubMed ID: 24035197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Transient Expression of Transgenic IL-12 in Mouse Liver Triggers Unremitting Inflammation Mimicking Human Autoimmune Hepatitis.
    Gil-Farina I; Di Scala M; Salido E; López-Franco E; Rodríguez-García E; Blasi M; Merino J; Aldabe R; Prieto J; Gonzalez-Aseguinolaza G
    J Immunol; 2016 Sep; 197(6):2145-56. PubMed ID: 27511737
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HLA class II influences humoral autoimmunity in patients with type 2 autoimmune hepatitis.
    Djilali-Saiah I; Fakhfakh A; Louafi H; Caillat-Zucman S; Debray D; Alvarez F
    J Hepatol; 2006 Dec; 45(6):844-50. PubMed ID: 17050030
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Requirements and challenges of a preclinical autoimmune hepatitis mouse model.
    Hardtke-Wolenski M; Noyan F; Jaeckel E
    Dig Dis; 2011; 29(4):402-10. PubMed ID: 21894011
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Activated farnesoid X receptor attenuates apoptosis and liver injury in autoimmune hepatitis.
    Lian F; Wang Y; Xiao Y; Wu X; Xu H; Liang L; Yang X
    Mol Med Rep; 2015 Oct; 12(4):5821-7. PubMed ID: 26238153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+ T cells.
    Hardtke-Wolenski M; Fischer K; Noyan F; Schlue J; Falk CS; Stahlhut M; Woller N; Kuehnel F; Taubert R; Manns MP; Jaeckel E
    Hepatology; 2013 Aug; 58(2):718-28. PubMed ID: 23475565
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Autoantibodies directed against the UDP-glucuronosyltransferases in human autoimmune hepatitis.
    Fabien N; Desbos A; Bienvenu J; Magdalou J
    Autoimmun Rev; 2004 Jan; 3(1):1-9. PubMed ID: 14871643
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.